A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2017-06-26
Target enrollment:
Participant gender:
Summary
This is a Phase I, randomized, placebo-controlled, double-blind study to evaluate the safety,
tolerability, pharmacokinetics, and preliminary activity of RO7105705 in two participant
populations: healthy participants and participants with mild-to-moderate Alzheimer's disease.
This study is a single dose, dose-escalation, and multiple dose study comprising
approximately six single dose cohorts in healthy participants administered RO7105705, either
intravenously (IV) or subcutaneously (SC), and comprising one or more multiple dose cohorts
in healthy participants administered RO7105705 IV every week (QW), a total of 4 doses, and
one or more multiple dose cohorts in participants with Alzheimer's disease administered
RO7105705 IV QW, a total of 4 doses.